Geneius Biotechnology
CEO: Alfred E. Slanetz, PhD
Geneius is developing an adoptive cell therapy technology that is designed to selectively unleash the patient’s immune response to cancer, and may do so in a more robust way than currently available approaches.
Geneius’ platform re-educates the patient’s own T cells to be responsive to overlooked antigens to deliver a specific and durable immune response that is less available to immune evasion. Planned applications will be for blood cancers and all solid tumors.